Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

P. Sonneveld, R. Hajek, A. Nagler, A. Spencer, J. Bladé, T. Robak, S.H. Zhuang, J.-L. Harousseau, R.Z. Orlowski, Dina Ben-Yehuda-Salz

Research output: Contribution to journalArticlepeer-review

69 Scopus citations


BACKGROUND. Recently, the authors reported improved time to disease progression (TTP) with a combination of pegylated liposomal doxorubicin (PLD) and bortezomib compared with bortezomib alone in a phase 3 randomized trial in patients with recurrent/refractory multiple myeloma (MM). In the current analysis, they determined 1) the efficacy of PLD plus bortezomib versus bortezomib alone in patients with MM who had failed on prior thalidomide/lenalidomide (immunomodulatory drug [IMiD]) treatment and 2) the efficacy and safety profile of PLD plus bortezomib in IMiD-exposed and IMiD-naive patients. METHODS. This prespecified analysis included 646 patients who were randomized to receive either PLD with bortezomib (n = 324; 194 IMiD-naive patients and 130 IMiD-exposed patients) or bortezomib alone (n = 322; 184 IMiD-naive patients and 138 IMiD-exposed patients). The primary efficacy endpoint was TTP, and secondary endpoints included overall survival, response rate, and safety. RESULTS. The median TTP was significantly longer with PLD plus bortezomib compared with bortezomib alone in IMiD-exposed patients (270 days vs 205 days). No statistical difference was noted with respect to TTP between IMiD-naive (295 days) versus IMiD-exposed (270 days) subgroups who received PLD plus bortezomib. A sustained trend favoring combination therapy was observed in analyses of overall survival. In patients who achieved a response, the response duration was comparable for IMiD-naive patients and IMiD-exposed patients in the combination treatment group and lasted a median of 310 days and 319 days, respectively. The incidence of grade 3/4 adverse events was similar with PLD plus bortezomib regardless of prior IMiD exposure. CONCLUSIONS. A significantly prolonged TTP was observed with combined PLD plus bortezomib combination therapy compared with bortezomib alone despite prior IMiD exposure. For the combination treatment arm in the IMiD-naive and IMiD-exposed subgroups, TTP was comparable. Similarly, the safety profile of the PLD plus bortezomib combination was unaltered by prior IMiD exposure. © 2008 American Cancer Society.
Original languageEnglish
Pages (from-to)1529-1537
Number of pages9
Issue number7
StatePublished - 2008

Bibliographical note

Export Date: 03 October 2022; Cited By: 68; Correspondence Address: P. Sonneveld; Department of Hematology, Erasmus MC, Center Location, 3000 CA Rotterdam, P.O. Box 2040, Netherlands; email:; CODEN: CANCA


  • Antineoplastic Combined Chemotherapy Protocols
  • Boronic Acids
  • Disease Progression
  • Doxorubicin
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Myeloma
  • Neoplasm Recurrence, Local
  • Polyethylene Glycols
  • Pyrazines
  • Salvage Therapy
  • Survival Rate
  • Thalidomide
  • bortezomib
  • doxorubicin
  • epirubicin
  • idarubicin
  • lenalidomide
  • mitoxantrone
  • thalidomide
  • adult
  • alopecia
  • article
  • bleeding
  • cancer combination chemotherapy
  • cancer patient
  • cancer survival
  • combination chemotherapy
  • comparative study
  • congestive heart failure
  • continuous infusion
  • controlled study
  • deep vein thrombosis
  • disease course
  • drug efficacy
  • drug exposure
  • drug fatality
  • drug response
  • drug safety
  • drug tolerability
  • drug withdrawal
  • febrile neutropenia
  • female
  • hand foot syndrome
  • heart arrhythmia
  • human
  • incidence
  • lung embolism
  • major clinical study
  • male
  • monotherapy
  • mucosa inflammation
  • multiple cycle treatment
  • multiple myeloma
  • neutropenia
  • overall survival
  • peripheral neuropathy
  • priority journal
  • recurrent cancer
  • stomatitis
  • treatment failure
  • treatment response
  • unspecified side effect
  • Bortezomib
  • Lenalidomide
  • Multiple myeloma
  • Pegylated liposomal doxorubicin
  • Recurrent
  • Refractory


Dive into the research topics of 'Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy'. Together they form a unique fingerprint.

Cite this